RE:RE:RE:RE:Keytruda resistance shown as a monotherapy in anal cancerThe facts show that ... pelareorep, when added to an immune checkpoint inhibitor, results in a 4 fold improvement in ORR, which demonstratres synergy with an immune checkpoint inhibitor and is considered a biomarker for future response rate.
Couldn't be much more factual or clearer than this.